Assessing the efficacy of cancer immunotherapies for individual patients is a complex process, often involving lengthy and costly in vivo studies. This can lead to delays in treatment initiation and suboptimal therapeutic choices, impacting patient outcomes.

Probiont is developing an organ-on-a-chip platform designed to replicate patient-specific tumor microenvironments. This microfluidic system allows for the rapid, in vitro screening of various immunotherapy agents against patient-derived cancer cells. By emulating key physiological functions, the platform provides quantitative data on drug response, enabling clinicians to identify the most effective treatment strategies for individual patients prior to administration. This approach aims to accelerate the selection of targeted therapies and improve treatment success rates.

Organ-on-a-chip microfluidic devices engineered to mimic patient-specific tumor microenvironments.

High-throughput screening capabilities for multiple immunotherapy agents simultaneously.

Integration of patient-derived tumor cells and relevant immune components within the microfluidic system.

Quantitative assessment of cellular responses, including immune cell infiltration and cytokine production.

Proprietary assay development for measuring drug efficacy and resistance mechanisms.

Data analytics pipeline for generating personalized treatment response profiles.

The primary target audience includes oncologists, pharmaceutical companies involved in immunotherapy drug development, and clinical research organizations seeking advanced tools for personalized medicine and predictive diagnostics.

Revenue is generated through fee-for-service testing contracts for immunotherapy efficacy assessment and licensing agreements for the organ-on-a-chip technology.